# US 2024/0390276 A1 · Ruxolitinib composition and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390276 A1
- Document ID: US20240390276A1
- Status: Published application
- Kind: A1
- Application number: 18/695,839
- Filed: 2022-10-20
- Published: 2024-11-28
- Earliest claimed: 2021-09-28
- Applicants: Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.
- Inventors: Jin YU; Yanhua LUO; Weirui QI; Xiaoxiao WU; Tingting YAN
- Web page: https://patentgrep.com/patent/US20240390276A1

## CPC

- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed in the present invention is a Ruxolitinib composition, comprising: Ruxolitinib or a pharmaceutically acceptable salt, an emulsifier, a co-emulsifier, a solvent, and an aqueous phase thereof. The emulsifier comprises one or more of polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil and vitamin E succinic acid. The co-emulsifier comprises propylene glycol monocaprylate. The solvent comprises one or more of propylene glycol, diethylene glycol monoethyl ether, and ethanol. The Ruxolitinib composition of the present invention has an ideal particle size and PDI. Furthermore, the present invention provides Ruxolitinib gel. Compared with a Ruxolitinib cream, the film-permeable efficiency is improved, and the stability of administration to the external skin under the condition of pH 5-7 can be satisfied; compared with the Ruxolitinib cream, as well as commercially available calcipotriol and Benvitimod, the present invention achieves a better drug effect in the aspect of psoriasis treatment.

## Claims

### Claim 1

A ruxolitinib composition, characterized in that the ruxolitinib composition contains a therapeutic agent and an emulsifier, wherein the therapeutic agent is ruxolitinib or a pharmaceutically acceptable salt thereof with a free base-based content of 0.5%-2.0% of the weight of the composition: the emulsifier is one or more of polyoxyethylene alkyl aryl ether, polyoxyethylene monolaurate, polyoxyethylene monolaurate, polyoxyethylene lauryl ether, polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, polyoxyethylene plant oil, polyoxyethylene monooleate, polyoxyethylene monolaurate, and vitamin E succinate, preferably one or more of polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, polyoxyethylene monooleate, polyoxyethylene monolaurate, and vitamin E succinate, and more preferably one or more of polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, and vitamin E succinate.

### Claim 2 (depends on 1)

The composition according to claim 1, characterized in that the emulsifier is one or more selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, and vitamin E succinate, wherein the polyoxyethylene hydrogenated castor oil is one or more selected from RH20, RH30, RH40, RH50, and RH60, preferably one of RH40 and RH60, and more preferably RH40: the polyoxyethylene castor oil is one or more selected from EL20, EL25, EL30, EL35, EL40, and EL60, preferably one or more of EL30, EL35, and EL40, and more preferably EL35: the vitamin E succinate is one or more selected from VE-TPGS 400, VE-TPGS 1000, and VE-TPGS1500, preferably VE-TPGS 1000; and the content of the emulsifier is 2%-30%, further preferably 3%-12% of the weight of the composition.

### Claim 3 (depends on 2)

The ruxolitinib composition according to claim 2, characterized in that the composition contains a co-emulsifier, which is propylene glycol monocaprylate, with a content of 0-10%, preferably 0-7% of the weight of the composition.

### Claim 4 (depends on 3)

The ruxolitinib composition according to claim 3, characterized in that the composition contains a solvent, which is one or more selected from propylene glycol, diethylene glycol monoethyl ether, and ethanol, with a content of 0-60%, preferably 0-50% of the weight of the composition.

### Claim 5 (depends on 4)

The ruxolitinib composition according to claim 4, characterized in that the composition contains an aqueous phase, which contains water and optionally excipients, wherein the excipients are selected from one or more of a pH regulator, an osmotic pressure regulator, a preservative, and an opacifying agent; and the sum of the contents of the aqueous phase, the therapeutic agent, the emulsifier, the co-emulsifier and the solvent is 100% by the weight of the composition.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A method for the preparation of the ruxolitinib composition of any one of claims 1-5, characterized in that the method comprises the steps of:
heating the therapeutic agent, the emulsifier, the co-emulsifier and/or the solvent to 30-70° C., preferably 35-60° C., stirring, followed by adding the aqueous phase to obtain the ruxolitinib composition.

### Claim 7 (depends on 1, 2, 3, 4, 5)

A method for the preparation of the ruxolitinib composition of any one of claims 1-5, characterized in that the method comprises the steps of:
mixing the therapeutic agent, the emulsifier, the co-emulsifier and/or the solvent, heating them to 30-70° C., preferably 35-60° C. while stirring until dissolved, then adding the emulsifier, stirring, followed by adding the aqueous phase to obtain the ruxolitinib composition.

### Claim 8 (depends on 1, 2, 3, 4, 5)

Use of the ruxolitinib composition of any one of claims 1-5 in the preparation of a pharmaceutical formulation, wherein the pharmaceutical formulation is selected from a capsule, a tablet, granules, micro pills, an ointment, a cream, and a gel.

### Claim 9 (depends on 1, 2, 3, 4, 5)

A ruxolitinib gel, characterized in that the gel contains the composition of any one of claims 1-5, and a gel material.

### Claim 10 (depends on 9)

The ruxolitinib gel according to claim 9, wherein the gel material is one or more selected from carbomer, gellan gum, guar gum, sodium carboxymethyl cellulose and hydroxypropyl cellulose, preferably carbomer, with a content of 0.10%-2.0%, further preferably 0.25%-1.0% of the weight of the gel.

### Claim 11

A ruxolitinib gel, characterized in that the ruxolitinib gel contains:
a therapeutic agent: ruxolitinib, or a pharmaceutically acceptable salt thereof;
an emulsifier: one or more of polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil and vitamin E succinate;
a co-emulsifier: propylene glycol monocaprylate;
a solvent: one or more of propylene glycol, diethylene glycol monoethyl ether, and ethanol;
a gel material: one or more of carbomer, methylcellulose, sodium carboxymethyl cellulose, chitosan, gellan gum, guar gum, sodium carboxymethyl cellulose, and hydroxypropyl cellulose; and
water q.s. to 100 wt %.

### Claim 12 (depends on 11)

The ruxolitinib gel according to claim 11, characterized in that the ruxolitinib gel contains:
a therapeutic agent: 0.5%-2.0% of ruxolitinib, or a pharmaceutically acceptable salt thereof (based on the free base);
an emulsifier: 2%-30% of one or more of polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, and vitamin E succinate;
a co-emulsifier: 0-20% of propylene glycol monocaprylate;
a solvent: 0-60%, preferably 0-50%, more preferably 2%-50% of one or more of propylene glycol, diethylene glycol monoethyl ether, and ethanol;
a gel material: 0.10%-2.0% of one or more of carbomer, methylcellulose, sodium carboxymethyl cellulose, chitosan, gellan gum, guar gum, sodium carboxymethyl cellulose, and hydroxypropyl cellulose; and
water q.s. to 100 wt %;
based on the total weight of the gel;
preferably, the ruxolitinib gel contains:
a therapeutic agent: 0.5%-2.0% of ruxolitinib, or a pharmaceutically acceptable salt thereof (based on the free base);
an emulsifier: 1%-10% of polyoxyethylene hydrogenated castor oil, 1%-20% of polyoxyethylene castor oil, and 0-20% of vitamin E succinate;
a co-emulsifier: 0-20% of propylene glycol monocaprylate;
a solvent: 1%-50% of propylene glycol, 1%-10% of diethylene glycol monoethyl ether, and 0-50% of ethanol;
a gel material: 0.10%-2.0% of carbomer; and
water q.s. to 100 wt %;
based on the total weight of the gel;
more preferably, the ruxolitinib gel contains:
a therapeutic agent: 0.5%-2.0% of ruxolitinib, or a pharmaceutically acceptable salt thereof (based on the free base);
an emulsifier: 1.0%-5.0% of polyoxyethylene hydrogenated castor oil, 1%-10% of polyoxyethylene castor oil, and 0-10% of vitamin E succinate;
a co-emulsifier: 0-10% of propylene glycol monocaprylate;
a solvent: 1%-45% of propylene glycol, 1%-5.0% of diethylene glycol monoethyl ether, and 0-40% of ethanol;
a gel material: 0.10%-2.0% of carbomer; and
water q.s. to 100 wt %;
based on the total weight of the gel;
further preferably, the ruxolitinib gel contains:
a therapeutic agent: 0.5%-2.0% of ruxolitinib, or a pharmaceutically acceptable salt thereof (based on the free base);
an emulsifier: 1%-2% of polyoxyethylene hydrogenated castor oil, 4%-10% of polyoxyethylene castor oil, and 0-5% of vitamin E succinate;
a co-emulsifier: 0-7% of propylene glycol monocaprylate;
a solvent: 5%-45% of propylene glycol, 2%-5% of diethylene glycol monoethyl ether, and 0-15% of ethanol;
a gel material: 0.25%-1.0% of carbomer; and
water q.s. to 100 wt %;
based on the total weight of the gel.

### Claim 13 (depends on 9, 10, 11, 12)

A method for the preparation of the ruxolitinib gel of any one of claims 9-12, wherein the method comprises the steps of:
mixing the ruxolitinib composition except the aqueous phase and heating to 30-70° C., preferably 35-60° C., stirring to make the excipient completely melted and the therapeutic agent dissolved, then uniformly stirring with swollen carbomer, followed by adding the aqueous phase to obtain the ruxolitinib gel.

### Claim 14 (depends on 1, 2, 3, 4, 5)

A method for treating a disease in a subject, comprising administering to the subject a therapeutically effective amount of the ruxolitinib composition of any one of claims 1-5, wherein the disease is one or more of dermatitis, psoriasis, vitiligo, hydradenitis, urticaria, and alopecia areata.

### Claim 15 (depends on 9, 10, 11, 12)

A method for treating a disease in a subject, comprising administering to the subject a therapeutically effective amount of the ruxolitinib gel of any one of claims 9-12, wherein the disease is one or more of dermatitis, psoriasis, vitiligo, hydradenitis, urticaria, and alopecia areata.
